医学中的治疗性抗体
Prerna Sharma1, Rahul V Joshi1, Robert Pritchard1
1Geisinger Commonwealth School of Medicine, Scranton, PA 18509, USA.
Molecules (Basel, Switzerland)
|September 28, 2023
概括
治疗性抗体,包括单克隆抗体,正在快速发展为癌症和自身免疫性疾病等疾病的治疗方法. 本综述探讨了它们的临床应用,进化和药物发现的未来潜力.
科学领域:
- 生物技术和制药科学 生物技术和制药科学
- 免疫学和医学 免疫学和医学
背景情况:
- 抗体工程取得了显著的进步,特别是在过去的10-15年里.
- 单克隆抗体现在是已批准的治疗和诊断手段,在疫情期间越来越突出.
- 抗体是治疗各种疾病的生物药物中增长最快的一类.
研究的目的:
- 提供关于治疗抗体当前环境的全面概述.
- 总结抗体疗法的临床相关性和应用在各个医学领域.
- 讨论抗体药物发现的进化,命名,风险和未来方向.
主要方法:
- 关于治疗抗体开发和应用的文献综述.
- 对临床相关性和疾病治疗环境的分析.
- 讨论抗体命名,治疗方法和不良影响.
主要成果:
- 抗体是治疗癌症和自身免疫性疾病的主要生物药物类别.
- 对抗体治疗和诊断的监管批准的显著增长.
- 已建立的临床实用性和扩展应用在各种医学领域.
结论:
- 治疗性抗体在现代医学中至关重要,随着不断的进步.
- 了解抗体进化,应用和风险对于未来的药物发现至关重要.
- 该领域对新的治疗方法和诊断工具有着巨大的前景.
相关概念视频
Antibody Actions
1.1K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.1K
Hybridoma Technology
14.9K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.9K
Microorganisms in Medicine and Therapeutics
49
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
49
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Tumor Immunotherapy
551
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
551
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
164
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
164


